AI assistant
GENEDRIVE PLC Board/Management Information 2021
7668_mang_2021-11-16_aca0802b-6f4a-41e7-84b4-6d2d19df37d7.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 4509S
Genedrive PLC
16 November 2021
genedrive plc
("genedrive" or the "Company")
Directorate Change
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the Group's Chief Financial Officer has notified the Board of his intention to stand down after five years in the role, in order to take up a position as Chief Financial Officer of musicMagpie plc.
Matthew Fowler will continue to fulfil the role of Chief Financial Officer for a period of time and his formal departure date will be communicated in due course. In the meantime, the Board will commence the search for a successor.
Ian Gilham, Chairman of genedrive, said; "I would like to thank Matthew for his contribution over the last five years. The Board and I wish him the very best for the future and in his new role."
For further details please contact:
| genedrive plc | ||
| David Budd: CEO / Matthew Fowler: CFO | +44 (0)161 989 0245 | |
| Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 | |
| James Steel | ||
| finnCap (Joint Broker) | +44 (0)20 7220 0500 | |
| Geoff Nash / Kate Bannatyne / Alice Lane | ||
| Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or [email protected] | |
| Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 | |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV and certain military biological targets. The Company recently released a high throughput SARS-CoV-2 assay and has a point of care version of the SARS-Cov-2 test due on market during 2021.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOAUVVWRASUAAAA